A phase 1b, multicenter, double-blind, randomized, placebo-controlled, crossover clinical trial of sitagliptin 100 mg and sitagliptin 200 mg in patients with type 2 diabetes mellitus who have inadequate glycemic control on diet and exercise.

Trial Profile

A phase 1b, multicenter, double-blind, randomized, placebo-controlled, crossover clinical trial of sitagliptin 100 mg and sitagliptin 200 mg in patients with type 2 diabetes mellitus who have inadequate glycemic control on diet and exercise.

Completed
Phase of Trial: Phase I

Latest Information Update: 15 May 2017

At a glance

  • Drugs Sitagliptin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms COMPLETED
  • Sponsors Merck & Co
  • Most Recent Events

    • 21 Feb 2013 Actual end date changed from Aug 2008 to Jul 2008 as reported by ClinicalTrials.gov.
    • 18 Apr 2009 Actual end date changed from Jul 2007 to Aug 2007 as reported by ClinicalTrials.gov.
    • 07 Aug 2008 Actual study completion date as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top